US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Bright Minds Biosciences

News headline image
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
Tickers AIFF CSE:DRUG DRUG
News headline image
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
News headline image
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG